What is the target range for systolic blood pressure (SBP) management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Target Systolic Blood Pressure Range

The target systolic blood pressure for most adults is 120-129 mmHg (Answer: A - 120-140 mmHg is closest, though the upper limit should be 129 mmHg, not 140 mmHg). 1

Primary Target for Most Adults

The 2024 European Society of Cardiology guidelines establish a Class I recommendation that treated systolic blood pressure should be targeted to 120-129 mmHg in most adults to reduce cardiovascular risk, provided treatment is well tolerated. 1

  • Within this range, 120 mmHg is the optimal point if tolerated 1
  • This target applies to both hypertensive patients (baseline BP ≥140/90 mmHg) and those with elevated BP receiving treatment 1
  • The diastolic target is 70-79 mmHg when systolic BP is at goal 1, 2

Stepwise Approach to Blood Pressure Targets

The initial objective should be to lower BP to <140/90 mmHg in all patients, then progress to the optimal target of 120-129 mmHg if well tolerated 1

  • This staged approach reduces the risk of adverse events while achieving cardiovascular benefit 3
  • Meta-analyses confirm that SBP <130 mmHg significantly reduces major cardiovascular disease (HR 0.78) and all-cause mortality (HR 0.89) compared to targets ≥130 mmHg 4

Important Exceptions Requiring More Lenient Targets

Older adults ≥65 years should target 130-139 mmHg 1, 2

Patients ≥85 years or with pre-treatment symptomatic orthostatic hypotension should consider targets <140 mmHg 1

Patients with clinically significant moderate-to-severe frailty at any age or limited predicted lifespan (<3 years) may consider targets <140/90 mmHg 1

When Target Cannot Be Achieved

If the 120-129 mmHg target is not tolerated, follow the "as low as reasonably achievable" (ALARA) principle 1

  • Avoid lowering BP below 120/70 mmHg, as excessive reduction may increase cardiovascular mortality 3
  • Monitor for signs of organ hypoperfusion including orthostatic hypotension, dizziness, weakness, and creatinine elevation 3
  • Diastolic BP <60 mmHg is associated with increased cardiovascular events when systolic BP is <130 mmHg 2

Evidence Base

The SPRINT trial demonstrated that intensive treatment (target <120 mmHg) reduced major cardiovascular events by 25% compared to standard treatment (target <140 mmHg) 2, 5

  • Recent meta-analyses support SBP targets <120 mmHg for reducing major CVD (HR 0.82) in selected populations 4
  • The 2024 ESC guidelines emphasize that an on-treatment systolic BP of 135 mmHg is not optimal relative to more intensive control 1

Common Pitfalls to Avoid

Do not confuse automated office BP (AOSBP) with usual office BP measurements - AOSBP is approximately 10-15 mmHg lower than usual office BP 6

Confirm BP with out-of-office measurements (ABPM or HBPM) before intensifying treatment to avoid overtreatment based on white-coat hypertension 1

Watch for increased adverse events with intensive treatment, including hypotension, syncope, electrolyte abnormalities, acute kidney injury, and falls, particularly in elderly patients 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.